CONNECT upgrade allows for flexibility, tailoring

The Federal Health Architecture (FHA) released CONNECT 4.2, an enhanced version of CONNECT 4—the dynamic open source platform designed to enable secure health information exchange.

CONNECT 4.2's features reflect the requirements specified by current CONNECT users and organizations looking to adopt this solution for enterprise interoperability and the sharing of health data. The new release includes includes the following:

  • Support for Java 6 and 7--WebSphere 7 and WebLogic 11g require Java 6, so CONNECT 4.2 now provides greater flexibility to deploy in an organization’s existing architecture.
  • Support for multi-specification document query and document retrieve version identification functions, including the initiating and responding messages function.
    This allows for increased tailoring and management of messages to a broader set of exchange partners.
  • Enhancements and defect resolutions identified as a result of participating in the Healtheway Product Certification Pilot Program. CONNECT users engage with the eHealth Exchange Community to identify test script improvements and CONNECT product enhancements. FHA said its goal is to "ensure CONNECT remains a robust product that organizations can leverage in a rapidly growing health data exchange environment."

Access the CONNECT Wiki and CONNECT 4.2 Release Notes for more information about the latest release.



 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.